Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Prostate Cancer

  Free Subscription

Articles published in Oncogene

Retrieve available abstracts of 95 articles:
HTML format

Single Articles

    June 2024
  1. FRANCIS JC, Capper A, Rust AG, Ferro K, et al
    Identification of genes that promote PI3K pathway activation and prostate tumour formation.
    Oncogene. 2024;43:1824-1835.
    PubMed     Abstract available

    May 2024
  2. ZHAO J, Shen J, Mao L, Yang T, et al
    Cancer associated fibroblast secreted miR-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer.
    Oncogene. 2024 May 20. doi: 10.1038/s41388-024-03057.
    PubMed     Abstract available

  3. TAHSIN S, Sane NS, Cernyar B, Jiang L, et al
    AR loss in prostate cancer stroma mediated by NF-kappaB and p38-MAPK signaling disrupts stromal morphogen production.
    Oncogene. 2024 May 20. doi: 10.1038/s41388-024-03064.
    PubMed     Abstract available

  4. BEIER AK, Ebersbach C, Siciliano T, Scholze J, et al
    Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer.
    Oncogene. 2024 May 15. doi: 10.1038/s41388-024-03059.
    PubMed     Abstract available

    April 2024
  5. RAWAT C, Heemers HV
    Alternative splicing in prostate cancer progression and therapeutic resistance.
    Oncogene. 2024 Apr 24. doi: 10.1038/s41388-024-03036.
    PubMed     Abstract available

  6. ARRIAGA JM, Ronaldson-Bouchard K, Picech F, Nunes de Almeida F, et al
    Correction: In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis.
    Oncogene. 2024 Apr 16. doi: 10.1038/s41388-024-03031.

  7. LI Y, Lv L, Ye M, Xie N, et al
    PDIA2 has a dual function in promoting androgen deprivation therapy induced venous thrombosis events and castrate resistant prostate cancer progression.
    Oncogene. 2024 Apr 8. doi: 10.1038/s41388-024-03024.
    PubMed     Abstract available

  8. CHEN M, Zou C, Tian Y, Li W, et al
    An integrated ceRNA network identifies miR-375 as an upregulated miRNA playing a tumor suppressive role in aggressive prostate cancer.
    Oncogene. 2024 Apr 2. doi: 10.1038/s41388-024-03011.
    PubMed     Abstract available

    March 2024
  9. YI Q, Han X, Yu HG, Chen HY, et al
    SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain.
    Oncogene. 2024 Mar 26. doi: 10.1038/s41388-024-02944.
    PubMed     Abstract available

  10. GUO S, Miao M, Wu Y, Pan D, et al
    DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer.
    Oncogene. 2024 Mar 13. doi: 10.1038/s41388-024-03005.
    PubMed     Abstract available

  11. ARRIAGA JM, Ronaldson-Bouchard K, Picech F, Nunes de Almeida F, et al
    In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis.
    Oncogene. 2024 Mar 7. doi: 10.1038/s41388-024-02995.
    PubMed     Abstract available

  12. LI J, Hong Z, Zhang J, Zheng S, et al
    Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.
    Oncogene. 2024;43:744-757.
    PubMed     Abstract available

    January 2024
  13. CHAO Y, Chen Y, Zheng W, Demanelis K, et al
    Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer.
    Oncogene. 2024 Jan 25. doi: 10.1038/s41388-024-02939.
    PubMed     Abstract available

  14. RODRIGUEZ TIRADO C, Wang C, Li X, Deng S, et al
    UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance.
    Oncogene. 2024;43:265-280.
    PubMed     Abstract available

    December 2023
  15. FERRARI MG, Jimenez-Uribe AP, Wang L, Hoeppner LH, et al
    Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target.
    Oncogene. 2023 Dec 23. doi: 10.1038/s41388-023-02925.
    PubMed     Abstract available

  16. MILLER KA, Degan S, Wang Y, Cohen J, et al
    Correction: PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.
    Oncogene. 2023 Dec 14. doi: 10.1038/s41388-023-02920.

  17. CHAUHAN SS, Casillas AL, Vizzerra AD, Liou H, et al
    PIM1 drives lipid droplet accumulation to promote proliferation and survival in prostate cancer.
    Oncogene. 2023 Dec 14. doi: 10.1038/s41388-023-02914.
    PubMed     Abstract available

    November 2023
  18. EIGENTLER A, Handle F, Schanung S, Degen A, et al
    Glucocorticoid treatment influences prostate cancer cell growth and the tumor microenvironment via altered glucocorticoid receptor signaling in prostate fibroblasts.
    Oncogene. 2023 Nov 29. doi: 10.1038/s41388-023-02901.
    PubMed     Abstract available

  19. CUI H, Wang Y, Zhou T, Qu L, et al
    Targeting DGAT1 inhibits prostate cancer cells growth by inducing autophagy flux blockage via oxidative stress.
    Oncogene. 2023 Nov 16. doi: 10.1038/s41388-023-02878.
    PubMed     Abstract available

    October 2023
  20. MILLER KA, Degan S, Wang Y, Cohen J, et al
    PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.
    Oncogene. 2023 Oct 24. doi: 10.1038/s41388-023-02875.
    PubMed     Abstract available

    September 2023
  21. ADVANI R, Luzzi S, Scott E, Dalgliesh C, et al
    Epithelial specific splicing regulator proteins as emerging oncogenes in aggressive prostate cancer.
    Oncogene. 2023 Sep 26. doi: 10.1038/s41388-023-02838.
    PubMed     Abstract available

    August 2023
  22. BUNAY J, Kossai M, Damon-Soubeyrant C, De Haze A, et al
    Persistent organic pollutants promote aggressiveness in prostate cancer.
    Oncogene. 2023 Aug 17. doi: 10.1038/s41388-023-02788.
    PubMed     Abstract available

  23. WU T, Zhang Y, Han Q, Lu X, et al
    Klotho-beta attenuates Rab8a-mediated exosome regulation and promotes prostate cancer progression.
    Oncogene. 2023 Aug 15. doi: 10.1038/s41388-023-02807.
    PubMed     Abstract available

    July 2023
  24. BUSKIN A, Scott E, Nelson R, Gaughan L, et al
    Engineering prostate cancer in vitro: what does it take?
    Oncogene. 2023 Jul 12. doi: 10.1038/s41388-023-02776.
    PubMed     Abstract available

  25. ZHOU Z, Jia D, Kwon O, Li S, et al
    Androgen-regulated stromal complement component 7 (C7) suppresses prostate cancer growth.
    Oncogene. 2023 Jul 3. doi: 10.1038/s41388-023-02759.
    PubMed     Abstract available

    June 2023
  26. VLAJIC K, Pennington Kluger H, Bie W, Merrill BJ, et al
    Appearance of tuft cells during prostate cancer progression.
    Oncogene. 2023 Jun 29. doi: 10.1038/s41388-023-02743.
    PubMed     Abstract available

  27. BLATT EB, Parra K, Neeb A, Buroni L, et al
    Critical role of antioxidant programs in enzalutamide-resistant prostate cancer.
    Oncogene. 2023 Jun 24. doi: 10.1038/s41388-023-02756.
    PubMed     Abstract available

    May 2023
  28. LIN Z, Agarwal S, Tan S, Shi H, et al
    Palmitoyl acyltransferase ZDHHC7 inhibits androgen receptor and suppresses prostate cancer.
    Oncogene. 2023 May 17. doi: 10.1038/s41388-023-02718.
    PubMed     Abstract available

    April 2023
  29. LI Z, Jiao X, Robertson AG, Di Sante G, et al
    The DACH1 gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, decreases DNA damage repair, and predicts therapy responses.
    Oncogene. 2023 Apr 24. doi: 10.1038/s41388-023-02668.
    PubMed     Abstract available

  30. KIM H, Barua A, Huang L, Zhou T, et al
    The cancer testis antigen TDRD1 regulates prostate cancer proliferation by associating with the snRNP biogenesis machinery.
    Oncogene. 2023 Apr 12. doi: 10.1038/s41388-023-02690.
    PubMed     Abstract available

  31. CAMERON S, Deblois G, Hawley JR, Qamra A, et al
    Chronic hypoxia favours adoption to a castration-resistant cell state in prostate cancer.
    Oncogene. 2023 Apr 5. doi: 10.1038/s41388-023-02680.
    PubMed     Abstract available

    March 2023
  32. YENDE AS, Williams EC, Pletcher A, Helfand A, et al
    TRIM28 promotes luminal cell plasticity in a mouse model of prostate cancer.
    Oncogene. 2023 Mar 8. doi: 10.1038/s41388-023-02655.
    PubMed     Abstract available

  33. NIKESITCH N, Beraldi E, Zhang F, Adomat H, et al
    Chaperone-mediated autophagy promotes PCa survival during ARPI through selective proteome remodeling.
    Oncogene. 2023;42:748-758.
    PubMed     Abstract available

  34. DING Y, Chen J, Li S, Wren JD, et al
    EWI2 and its relatives in Tetraspanin-enriched membrane domains regulate malignancy.
    Oncogene. 2023;42:861-868.
    PubMed     Abstract available

    February 2023
  35. GRITSINA G, Yu J
    CXCR7 as a novel therapeutic target for advanced prostate cancer.
    Oncogene. 2023 Feb 9. doi: 10.1038/s41388-023-02597.
    PubMed     Abstract available

  36. SCOTT E, Hodgson K, Calle B, Turner H, et al
    Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.
    Oncogene. 2023 Feb 1. doi: 10.1038/s41388-023-02604.
    PubMed     Abstract available

    January 2023
  37. YANG JC, Xu P, Ning S, Wasielewski LJ, et al
    Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.
    Oncogene. 2023 Jan 3. doi: 10.1038/s41388-022-02566.
    PubMed     Abstract available

    December 2022
  38. FAN L, Gong Y, He Y, Gao WQ, et al
    TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer.
    Oncogene. 2022 Dec 21. doi: 10.1038/s41388-022-02498.
    PubMed     Abstract available

    October 2022
  39. KIKUNO N, Shiina H, Urakami S, Kawamoto K, et al
    Retraction Note: Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity.
    Oncogene. 2022 Oct 19. pii: 10.1038/s41388-022-02501.

  40. GUO Y, He J, Zhang H, Chen R, et al
    Linear ubiquitination of PTEN impairs its function to promote prostate cancer progression.
    Oncogene. 2022 Oct 3. pii: 10.1038/s41388-022-02485.
    PubMed     Abstract available

  41. TAN Q, Liu Z, Gao X, Wang Y, et al
    Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors.
    Oncogene. 2022;41:4754-4767.
    PubMed     Abstract available

    September 2022
  42. AHN S, Saha A, Clark R, Kolonin MG, et al
    CXCR4 and CXCR7 signaling promotes tumor progression and obesity-associated epithelial-mesenchymal transition in prostate cancer cells.
    Oncogene. 2022 Sep 10. pii: 10.1038/s41388-022-02466.
    PubMed     Abstract available

  43. WANG C, Li W, Hu Q, Feng N, et al
    Transgenic construction and functional miRNA analysis identify the role of miR-7 in prostate cancer suppression.
    Oncogene. 2022 Sep 10. pii: 10.1038/s41388-022-02461.
    PubMed     Abstract available

  44. WANG X, Brea L, Lu X, Gritsina G, et al
    FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A.
    Oncogene. 2022;41:4259-4270.
    PubMed     Abstract available

  45. LI C, Liu J, He D, Mao F, et al
    GSTM2 is a key molecular determinant of resistance to SG-ARIs.
    Oncogene. 2022;41:4498-4511.
    PubMed     Abstract available

    August 2022
  46. WANG J, Li J, Yin L, Pu T, et al
    Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer.
    Oncogene. 2022 Aug 19. pii: 10.1038/s41388-022-02437.
    PubMed     Abstract available

  47. MOUILLET-RICHARD S, Martin-Lanneree S, Le Corre D, Hirsch TZ, et al
    A proof of concept for targeting the PrP(C) - Amyloid beta peptide interaction in basal prostate cancer and mesenchymal colon cancer.
    Oncogene. 2022 Aug 12. pii: 10.1038/s41388-022-02430.
    PubMed     Abstract available

  48. IPSEN MB, Sorensen EMG, Thomsen EA, Weiss S, et al
    A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer.
    Oncogene. 2022 Aug 6. pii: 10.1038/s41388-022-02427.
    PubMed     Abstract available

    July 2022
  49. LI Z, Li B, Yu H, Wang P, et al
    DNMT1-mediated epigenetic silencing of TRAF6 promotes prostate cancer tumorigenesis and metastasis by enhancing EZH2 stability.
    Oncogene. 2022 Jul 8. pii: 10.1038/s41388-022-02404.
    PubMed     Abstract available

  50. WENTA T, Schmidt A, Zhang Q, Devarajan R, et al
    Disassembly of alpha6beta4-mediated hemidesmosomal adhesions promotes tumorigenesis in PTEN-negative prostate cancer by targeting plectin to focal adhesions.
    Oncogene. 2022 Jul 1. pii: 10.1038/s41388-022-02389.
    PubMed     Abstract available

    June 2022
  51. DUTTA S, Polavaram NS, Islam R, Bhattacharya S, et al
    Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer.
    Oncogene. 2022 Jun 27. pii: 10.1038/s41388-022-02382.
    PubMed     Abstract available

  52. SUN F, Wang X, Hu J, Liu J, et al
    RUVBL1 promotes enzalutamide resistance of prostate tumors through the PLXNA1-CRAF-MAPK pathway.
    Oncogene. 2022;41:3239-3250.
    PubMed     Abstract available

    May 2022
  53. KHANDRIKA L, Lieberman R, Koul S, Kumar B, et al
    Retraction Note: Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1alpha levels contribute to emergence of an aggressive phenotype in prostate cancer.
    Oncogene. 2022 May 19. pii: 10.1038/s41388-022-02357.

  54. CONSTANTIN TA, Greenland KK, Varela-Carver A, Bevan CL, et al
    Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer.
    Oncogene. 2022 May 14. pii: 10.1038/s41388-022-02347.
    PubMed     Abstract available

  55. EHSANI M, Bartsch S, Rasa SMM, Dittmann J, et al
    The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer through angiopoietin 2.
    Oncogene. 2022 May 5. pii: 10.1038/s41388-022-02333.
    PubMed     Abstract available

  56. JI D, Shang G, Wei E, Jia Y, et al
    Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer.
    Oncogene. 2022 May 5. pii: 10.1038/s41388-022-02327.
    PubMed     Abstract available

  57. ZHANG Y, Xu Z, Wen W, Liu Z, et al
    The microRNA-3622 family at the 8p21 locus exerts oncogenic effects by regulating the p53-downstream gene network in prostate cancer progression.
    Oncogene. 2022 May 2. pii: 10.1038/s41388-022-02289.
    PubMed     Abstract available

    April 2022
  58. GAO P, Hao JL, Xie QW, Han GQ, et al
    PELO facilitates PLK1-induced the ubiquitination and degradation of Smad4 and promotes the progression of prostate cancer.
    Oncogene. 2022 Apr 18. pii: 10.1038/s41388-022-02316.
    PubMed     Abstract available

  59. LIN HY, Ko CJ, Lo TY, Wu SR, et al
    Matriptase-2/NR4A3 axis switches TGF-beta action toward suppression of prostate cancer cell invasion, tumor growth, and metastasis.
    Oncogene. 2022 Apr 13. pii: 10.1038/s41388-022-02303.
    PubMed     Abstract available

  60. COPELLO VA, Burnstein KL
    The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor.
    Oncogene. 2022 Apr 13. pii: 10.1038/s41388-022-02307.
    PubMed     Abstract available

  61. BRAMHECHA YM, Guerard KP, Audet-Walsh E, Rouzbeh S, et al
    Fatty acid oxidation enzyme Delta3, Delta2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients.
    Oncogene. 2022 Apr 11. pii: 10.1038/s41388-022-02276.
    PubMed     Abstract available

    March 2022
  62. WANG C, Leavenworth J, Zhang C, Liu Z, et al
    Epigenetic regulation of EIF4A1 through DNA methylation and an oncogenic role of eIF4A1 through BRD2 signaling in prostate cancer.
    Oncogene. 2022 Mar 31. pii: 10.1038/s41388-022-02272.
    PubMed     Abstract available

  63. WANG L, Wang J, Yin X, Guan X, et al
    GIPC2 interacts with Fzd7 to promote prostate cancer metastasis by activating WNT signaling.
    Oncogene. 2022 Mar 28. pii: 10.1038/s41388-022-02255.
    PubMed     Abstract available

    February 2022
  64. DE WET L, Williams A, Gillard M, Kregel S, et al
    Correction to: SOX2 mediates metabolic reprogramming of prostate cancer cells.
    Oncogene. 2022 Feb 10. pii: 10.1038/s41388-022-02228.

    January 2022
  65. YI Y, Li Y, Li C, Wu L, et al
    Methylation-dependent and -independent roles of EZH2 synergize in CDCA8 activation in prostate cancer.
    Oncogene. 2022 Jan 29. pii: 10.1038/s41388-022-02208.
    PubMed     Abstract available

  66. MELNYK JE, Steri V, Nguyen HG, Hwang YC, et al
    Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCbeta1.
    Oncogene. 2022 Jan 27. pii: 10.1038/s41388-022-02179.
    PubMed     Abstract available

  67. DE WET L, Williams A, Gillard M, Kregel S, et al
    SOX2 mediates metabolic reprogramming of prostate cancer cells.
    Oncogene. 2022 Jan 24. pii: 10.1038/s41388-021-02157.
    PubMed     Abstract available

  68. XU L, Zhao B, Butler W, Xu H, et al
    Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer.
    Oncogene. 2022 Jan 20. pii: 10.1038/s41388-021-02155.
    PubMed     Abstract available

  69. CANNISTRACI A, Hascoet P, Ali A, Mundra P, et al
    MiR-378a inhibits glucose metabolism by suppressing GLUT1 in prostate cancer.
    Oncogene. 2022 Jan 17. pii: 10.1038/s41388-022-02178.
    PubMed     Abstract available

  70. HAN W, Liu M, Han D, Li M, et al
    RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition.
    Oncogene. 2022 Jan 3. pii: 10.1038/s41388-021-02135.
    PubMed     Abstract available

  71. MCCANN JJ, Vasilevskaya IA, McNair C, Gallagher P, et al
    Mutant p53 elicits context-dependent pro-tumorigenic phenotypes.
    Oncogene. 2022;41:444-458.
    PubMed     Abstract available

  72. ZHANG B, Zhang M, Yang Y, Li Q, et al
    Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC.
    Oncogene. 2022;41:387-399.
    PubMed     Abstract available

    December 2021
  73. MIRZAKHANI K, Kallenbach J, Rasa SMM, Ribaudo F, et al
    Correction to: The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.
    Oncogene. 2021 Dec 20. pii: 10.1038/s41388-021-02125.

    November 2021
  74. LEE YC, Lin SC, Yu G, Zhu M, et al
    Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition.
    Oncogene. 2021 Nov 29. pii: 10.1038/s41388-021-02131.
    PubMed     Abstract available

  75. MAZZU YZ, Liao YR, Nandakumar S, Jehane LE, et al
    Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer.
    Oncogene. 2021 Nov 20. pii: 10.1038/s41388-021-02118.
    PubMed     Abstract available

    October 2021
  76. CHERIF C, Nguyen DT, Paris C, Le TK, et al
    Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity.
    Oncogene. 2021 Oct 28. pii: 10.1038/s41388-021-02039.
    PubMed     Abstract available

  77. MIRZAKHANI K, Kallenbach J, Rasa SMM, Ribaudo F, et al
    The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.
    Oncogene. 2021 Oct 19. pii: 10.1038/s41388-021-02060.
    PubMed     Abstract available

  78. HU L, Chen X, Narwade N, Lim MGL, et al
    Single-cell analysis reveals androgen receptor regulates the ER-to-Golgi trafficking pathway with CREB3L2 to drive prostate cancer progression.
    Oncogene. 2021 Oct 5. pii: 10.1038/s41388-021-02026.
    PubMed     Abstract available

    September 2021
  79. LABANCA E, Bizzotto J, Sanchis P, Anselmino N, et al
    Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel.
    Oncogene. 2021 Sep 28. pii: 10.1038/s41388-021-02008.
    PubMed     Abstract available

  80. ZHU M, Peng R, Liang X, Lan Z, et al
    P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis.
    Oncogene. 2021 Sep 1. pii: 10.1038/s41388-021-02000.
    PubMed     Abstract available

    August 2021
  81. PARK SH, Fong KW, Mong E, Martin MC, et al
    Going beyond Polycomb: EZH2 functions in prostate cancer.
    Oncogene. 2021 Aug 4. pii: 10.1038/s41388-021-01982.
    PubMed     Abstract available

    July 2021
  82. LIU C, Armstrong CM, Ning S, Yang JC, et al
    ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling.
    Oncogene. 2021 Jul 16. pii: 10.1038/s41388-021-01914.
    PubMed     Abstract available

    June 2021
  83. HAGIWARA M, Fushimi A, Yamashita N, Bhattacharya A, et al
    MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells.
    Oncogene. 2021 Jun 23. pii: 10.1038/s41388-021-01899.
    PubMed     Abstract available

  84. LAUNONEN KM, Paakinaho V, Sigismondo G, Malinen M, et al
    Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells.
    Oncogene. 2021 Jun 14. pii: 10.1038/s41388-021-01887.
    PubMed     Abstract available

  85. PAN T, Lin SC, Lee YC, Yu G, et al
    Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone.
    Oncogene. 2021 Jun 14. pii: 10.1038/s41388-021-01874.
    PubMed     Abstract available

  86. LIAO Y, Liu Y, Shao Z, Xia X, et al
    A new role of GRP75-USP1-SIX1 protein complex in driving prostate cancer progression and castration resistance.
    Oncogene. 2021 Jun 2. pii: 10.1038/s41388-021-01851.
    PubMed     Abstract available

    May 2021
  87. LEE HC, Ou CH, Huang YC, Hou PC, et al
    Correction: YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer.
    Oncogene. 2021 May 19. pii: 10.1038/s41388-021-01836.

  88. CRONIN R, Brooke GN, Prischi F
    The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance.
    Oncogene. 2021 May 10. pii: 10.1038/s41388-021-01810.
    PubMed     Abstract available

  89. ZHU Y, Dalrymple SL, Coleman I, Zheng SL, et al
    Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
    Oncogene. 2021 May 6. pii: 10.1038/s41388-021-01805.

    April 2021
  90. WATSON MJ, Berger PL, Banerjee K, Frank SB, et al
    Aberrant CREB1 activation in prostate cancer disrupts normal prostate luminal cell differentiation.
    Oncogene. 2021 Apr 12. pii: 10.1038/s41388-021-01772.
    PubMed     Abstract available

  91. PUHR M, Eigentler A, Handle F, Hackl H, et al
    Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer.
    Oncogene. 2021 Apr 1. pii: 10.1038/s41388-021-01754.
    PubMed     Abstract available

  92. PURAYIL HT, Zhang Y, Black JB, Gharaibeh R, et al
    Nuclear betaArrestin1 regulates androgen receptor function in castration resistant prostate cancer.
    Oncogene. 2021;40:2610-2620.
    PubMed     Abstract available

  93. ZHOU J, Wang Y, Wu D, Wang S, et al
    Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer.
    Oncogene. 2021;40:2625-2634.
    PubMed     Abstract available

    February 2021
  94. LIU PI, Chang AC, Lai JL, Lin TH, et al
    Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases.
    Oncogene. 2021;40:1503-1515.
    PubMed     Abstract available

    January 2021
  95. KWON OJ, Zhang L, Jia D, Xin L, et al
    Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation from Pten null Sca-1(+) prostate luminal cells.
    Oncogene. 2021;40:203-214.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.